Last reviewed · How we verify
Symptomatic drugs
Symptomatic drugs is a Small molecule drug developed by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta. It is currently FDA-approved for Symptomatic management of neurological disorders.
Symptomatic drugs provide relief from disease symptoms without targeting the underlying pathological mechanism.
Riociguat, a hydrolytic enzyme inhibitor, is used to treat symptomatic conditions such as pulmonary hypertension associated with idiopathic interstitial pneumonias and benign prostatic hyperplasia. It works by inhibiting the enzyme methotrexate hydrolytic enzyme, which is involved in folate metabolism.
At a glance
| Generic name | Symptomatic drugs |
|---|---|
| Sponsor | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Symptomatic treatment addresses the clinical manifestations and discomfort associated with a disease or condition, improving patient quality of life and functional status. These drugs do not modify disease progression or cure the underlying condition, but rather manage specific symptoms such as pain, tremor, spasticity, or other neurological manifestations. This approach is commonly used in neurology when disease-modifying therapies are unavailable or as adjunctive treatment.
Approved indications
- Symptomatic management of neurological disorders
Common side effects
Key clinical trials
- Iadademstat + SBRT With Atezo in ES-SCLC (PHASE1)
- OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
- A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease (PHASE3)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery" (NA)
- Brazilian Prospective Registry of the Inspiron EVO Drug-Eluting Stent in Complex Coronary Lesions
- Insertable Cardiac Monitor for Primary Atrial Fibrillation Detection in High-Risk Heart Failure Patients (NA)
- Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic Management
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Symptomatic drugs CI brief — competitive landscape report
- Symptomatic drugs updates RSS · CI watch RSS
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta portfolio CI
Frequently asked questions about Symptomatic drugs
What is Symptomatic drugs?
How does Symptomatic drugs work?
What is Symptomatic drugs used for?
Who makes Symptomatic drugs?
What development phase is Symptomatic drugs in?
Related
- Manufacturer: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Symptomatic management of neurological disorders
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing